EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognostic Value of Liver Stiffness in Advanced Chronic Liver Disease After Hepatitis C Virus Eradication

Federica Cerini iD, Mariagrazia Rumi iD, Jonas Schropp iD, Agostino Cosenza, Carmelo Selvaggio, Chiara Masellis, Annalisa Berzigotti iD

Liver International · 2026

DOI: 10.1111/liv.70869 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, 2026. Verfasst von Federica Cerini und 6 weiteren Autor:innen. Beteiligte Einrichtung: Hepatology Unit, San Giuseppe Hospital, University of Milan, Milan, Italy. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis C, Chronic, Liver, Liver Cirrhosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background & Aim Sustained‐virological‐response (SVR) after direct‐acting‐antiviral (DAA) therapy improves outcomes in patients with HCV‐related compensated‐advanced‐chronic‐liver‐disease (cACLD). However, it remains unclear whether absolute post‐SVR LSM or LSM reduction better predicts prognosis after SVR. This study evaluated the prognostic performance of absolute‐values‐LSM versus dynamic‐change for predicting liver‐related‐events after SVR.

Methods

We retrospectively analysed patients with HCV‐related cACLD treated with DAA between December 2014 and March 2022. Baseline and post‐SVR non‐invasive tests (LSM, FIB‐4 and APRI) were assessed. Predictive performance for liver‐related events was evaluated using time‐dependent receiver operating characteristic analysis. Associations between Baveno‐VII criteria for clinically significant LSM improvement and clinical outcomes were assessed using Fine–Grey competing‐risk models.

Results

During a median of 60 months (95%; CI 52–69), 11/135 patients (8%) developed liver‐related events. Patients who developed events had higher baseline LSM than those who remained event‐free (24 vs. 18 kPa, p = 0.049), and higher follow‐up LSM values (20 vs. 12 kPa, p = 0.043). Follow‐up LSM showed good discriminative ability for liver‐related events within the first 3 years after SVR (tAUC at 2 years: 0.86 [95% CI 0.75–0.97]; tAUC at 3 years: 0.82 [0.71–0.93]). Follow‐up LSM was significantly superior to ΔLSM and percentage ΔLSM at both 2 and 3 years (all p ≤ 0.028). In competing‐risk analysis, only follow‐up LSM > 20 kPa was significantly associated with liver‐related events (subdistribution hazard ratio 5.61, p = 0.007), whereas Baveno‐VII criteria for LSM regression were not (SHR 0.33, p = 0.097).

Conclusions

Absolute post‐treatment‐LSM provides stronger prognostic information than dynamic changes from baseline. These findings support repeated post‐SVR LSM assessment for risk stratification suggesting the relevance of residual liver disease in predicting liver‐related outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsHepatitis C, ChronicLiverLiver CirrhosisHumansRetrospective StudiesPrognosisFemaleSustained Virologic ResponseMaleMiddle AgedElasticity Imaging TechniquesROC CurvePredictive Value of Tests

Stichwörter der Autor:innen

advanced chronic liver diseaseliver cirrhosisliver related eventsliver stiffness measurement

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Hepatology Unit, San Giuseppe Hospital, University of Milan, Milan, Italy.
  • Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
  • Department for Visceral Medicine and Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Department of Biomedical Research, University of Bern, Bern, Switzerland.
  • Bavarian Center for Digital Health and Social Care, Kempten University of Applied Sciences, Kempten, Germany.
  • Graduate School for Health Sciences, University of Bern, Bern, Switzerland.

ORCID-Profile: Federica Cerini, Mariagrazia Rumi, Jonas Schropp, Annalisa Berzigotti

Zitieren

APA

Cerini, F., Rumi, M., Schropp, J., Cosenza, A., Selvaggio, C., Masellis, C., & Berzigotti, A. (2026). Prognostic Value of Liver Stiffness in Advanced Chronic Liver Disease After Hepatitis C Virus Eradication. Liver International. https://doi.org/10.1111/liv.70869

Vancouver

Cerini F, Rumi M, Schropp J, Cosenza A, Selvaggio C, Masellis C, et al. Prognostic Value of Liver Stiffness in Advanced Chronic Liver Disease After Hepatitis C Virus Eradication. Liver International. 2026. doi:10.1111/liv.70869

BibTeX
@article{Cerini2026,
  author = {Cerini, Federica and Rumi, Mariagrazia and Schropp, Jonas and Cosenza, Agostino and Selvaggio, Carmelo and Masellis, Chiara and Berzigotti, Annalisa},
  title = {Prognostic Value of Liver Stiffness in Advanced Chronic Liver Disease After Hepatitis C Virus Eradication},
  journal = {Liver International},
  year = {2026},
  doi = {10.1111/liv.70869}
}
Kostenlos starten →